Human Genetics Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé, MetaboHUB, 91191 Gif sur Yvette, France.
Am J Hum Genet. 2021 Jun 3;108(6):1040-1052. doi: 10.1016/j.ajhg.2021.04.013. Epub 2021 May 7.
SLC37A4 encodes an endoplasmic reticulum (ER)-localized multitransmembrane protein required for transporting glucose-6-phosphate (Glc-6P) into the ER. Once transported into the ER, Glc-6P is subsequently hydrolyzed by tissue-specific phosphatases to glucose and inorganic phosphate during times of glucose depletion. Pathogenic variants in SLC37A4 cause an established recessive disorder known as glycogen storage disorder 1b characterized by liver and kidney dysfunction with neutropenia. We report seven individuals who presented with liver dysfunction multifactorial coagulation deficiency and cardiac issues and were heterozygous for the same variant, c.1267C>T (p.Arg423), in SLC37A4; the affected individuals were from four unrelated families. Serum samples from affected individuals showed profound accumulation of both high mannose and hybrid type N-glycans, while N-glycans in fibroblasts and undifferentiated iPSC were normal. Due to the liver-specific nature of this disorder, we generated a CRISPR base-edited hepatoma cell line harboring the c.1267C>T (p.Arg423) variant. These cells replicated the secreted abnormalities seen in serum N-glycosylation, and a portion of the mutant protein appears to relocate to a distinct, non-Golgi compartment, possibly ER exit sites. These cells also show a gene dosage-dependent alteration in the Golgi morphology and reduced intraluminal pH that may account for the altered glycosylation. In summary, we identify a recurrent mutation in SLC37A4 that causes a dominantly inherited congenital disorder of glycosylation characterized by coagulopathy and liver dysfunction with abnormal serum N-glycans.
SLC37A4 编码一种内质网 (ER) 定位的多跨膜蛋白,该蛋白负责将葡萄糖-6-磷酸 (Glc-6P) 转运到 ER 中。一旦转运到 ER 中,Glc-6P 就会在葡萄糖耗竭时被组织特异性磷酸酶水解为葡萄糖和无机磷酸。SLC37A4 中的致病性变异导致一种已确立的隐性疾病,称为糖原贮积症 1b,其特征为肝和肾功能障碍伴中性粒细胞减少。我们报告了 7 名个体,他们表现为肝功能障碍、多因素凝血缺陷和心脏问题,并且杂合了 SLC37A4 中的相同变体 c.1267C>T (p.Arg423);受影响的个体来自四个无关的家庭。受影响个体的血清样本显示高甘露糖和杂合型 N-聚糖的大量积累,而成纤维细胞和未分化的 iPSC 中的 N-聚糖正常。由于该疾病具有肝脏特异性,我们生成了携带 c.1267C>T (p.Arg423) 变体的 CRISPR 碱基编辑肝癌细胞系。这些细胞复制了血清 N-糖基化中观察到的分泌异常,部分突变蛋白似乎重新定位到一个不同的、非高尔基体隔室,可能是内质网出口部位。这些细胞还表现出高尔基体形态的基因剂量依赖性改变和腔内 pH 值降低,这可能是糖基化改变的原因。总之,我们在 SLC37A4 中鉴定出一种复发性突变,该突变导致一种显性遗传的先天性糖基化紊乱,其特征为凝血功能障碍和肝功能障碍,伴有异常的血清 N-聚糖。